U.S. Markets closed
  • S&P 500

    3,236.92
    -78.65 (-2.37%)
     
  • Nasdaq

    10,632.99
    -330.65 (-3.02%)
     
  • Russell 2000

    1,451.46
    -45.50 (-3.04%)
     
  • Crude Oil

    39.18
    -0.75 (-1.88%)
     
  • Gold

    1,856.80
    -11.60 (-0.62%)
     
  • Silver

    22.03
    -1.07 (-4.65%)
     
  • EUR/USD

    1.1662
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    0.6760
    +0.0120 (+1.81%)
     
  • Vix

    28.58
    +1.72 (+6.40%)
     
  • GBP/USD

    1.2720
    -0.0006 (-0.0483%)
     
  • BTC-USD

    10,225.54
    -316.22 (-3.00%)
     
  • CMC Crypto 200

    207.71
    -6.26 (-2.92%)
     
  • FTSE 100

    5,899.26
    +69.80 (+1.20%)
     
  • Nikkei 225

    23,346.49
    -13.81 (-0.06%)
     

Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting

HOUSTON, April 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Annual Meeting, taking place from April 27-28, 2020.

Dr. Ana Tari Ashizawa, Senior Vice President of Research, Development and Clinical Design, at Bio-Path Holdings will summarize the Phase 1 study design of BP1002 (liposomal Bcl-2 antisense), the Company’s second drug candidate, for the treatment of lymphomas and chronic lymphocytic leukemia.  
                                                           
Details for the virtual poster presentation are as follows:

Date: Monday, April 27, 2020
Poster Release Time:  12:01 am Eastern Time
Session: Phase I Trials In Progress
Abstract: 9464
Title: “A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients with Advanced Lymphoid Malignancies”

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and has filed an IND for a Phase 1 clinical trial for solid tumors. The Company’s second pipeline candidate is BP1002, which targets the Bcl-2 protein and is planned to be evaluated for the treatment of lymphoma and chronic lymphocytic leukemia. In addition, an IND application for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, is expected to be filed in 2020.

For more information, please visit the Company's website at
http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369